OmniAb (OABI) Projected to Post Quarterly Earnings on Tuesday

OmniAb (NASDAQ:OABI) is expected to announce its earnings results after the market closes on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $10.13 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

OmniAb Stock Up 3.1 %

NASDAQ:OABI opened at $3.31 on Monday. OmniAb has a 12-month low of $3.05 and a 12-month high of $5.72. The firm has a market capitalization of $467.42 million, a P/E ratio of -5.34 and a beta of -0.14. The stock’s fifty day simple moving average is $3.43 and its 200-day simple moving average is $3.81.

Insider Transactions at OmniAb

In other news, CFO Kurt A. Gustafson sold 7,255 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total value of $26,625.85. Following the transaction, the chief financial officer now directly owns 206,211 shares in the company, valued at $756,794.37. This trade represents a 3.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Charles S. Berkman sold 25,489 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now directly owns 343,190 shares in the company, valued at $1,111,935.60. The trade was a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock worth $376,601 in the last three months. Insiders own 8.60% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.